Table 2 Pharmacotherapy profile in patients with NSTE-ACS according to age category
Medication | <65 Years | ≥ 65 Years | p value |
|---|---|---|---|
N (%) | |||
Aspirina | 133 (98.5%) | 68 (98.5%) | 0.9 |
P2Y12 inhibitor | 134 (99.3%) | 65 (100%) | 0.4 |
Heparin | 97 (71.9%) | 46 (70.8%) | 0.8 |
B-blockers | 105 (77.8%) | 49 (75.4%) | 0.7 |
Nitrate | 80 (59.3%) | 42 (64.6%) | 0.4 |
Calcium channel blockers | 11 (8.1%) | 10 (15.4%) | 0.1 |
ACEI/ARBs | 57 (42.2%) | 27 (41.5%) | 0.9 |
Statin | 123 (91.1%) | 53 (81.5%) | 0.051 |
Mineralocorticoid receptor antagonist | 9 (6.7%) | 12 (18.5%) | 0.01 |
Loop diuretics | 21 (15.6%) | 16 (24.6%) | 0.1 |